Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

This leads to relatively smooth (though not flawless) northbound trajectories and strong returns for most stocks over a ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded rating to 'Buy.' Discover why!

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

Vertex gained approval for two new products, its novel non-opioid pain medicine Journavx (suzetrigine) and its fifth CF medicine, Alyftrek, in the last few months. Vertex and partner CRISPR ...

Other product revenues included $14.2 million in sales of Casgevy, an insignificant amount from the newly approved pain drug, Journavx (suzetrigine) as well as sales of VRTX’s other CF products ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...